[
    [
        {
            "time": "2018-03-15",
            "original_text": "U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta",
            "features": {
                "keywords": [
                    "FDA",
                    "approves",
                    "Mylan",
                    "generic",
                    "Lilly",
                    "lung cancer",
                    "Alimta"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-16",
            "original_text": "Mylan Stock Leaps As It Prepares To Knock Off $2 Billion Lilly Drug",
            "features": {
                "keywords": [
                    "Mylan",
                    "Stock",
                    "Leaps",
                    "Knock Off",
                    "Lilly",
                    "Drug"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Mylan Stock Leaps As It Prepares To Knock Off $2 Billion Lilly Drug",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-17",
            "original_text": "Lilly (LLY) Up 1.9% Since Last Earnings Report: Can It Continue?",
            "features": {
                "keywords": [
                    "Lilly",
                    "LLY",
                    "Up",
                    "Earnings",
                    "Report"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly (LLY) Up 1.9% Since Last Earnings Report: Can It Continue?",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]